IMMUNOTHERAPY

This study tests a combination of three treatments—immunotherapy (tislelizumab), targeted therapy (afatinib), and a modified herpes virus (lysogenic HSV)—given before surgery for head and neck squamous cell carcinoma. The goal is to see if this approach safely shrinks tumors and …

This study tests a new treatment plan for people with advanced esophageal cancer that cannot be surgically removed. Participants first receive immunotherapy plus chemotherapy, followed by chemoradiation. The goal is to see if this approach improves survival and controls the disea…

This study tests whether combining an immunotherapy drug (pembrolizumab) with another immune-boosting protein (eftilagimod alpha) and radiation therapy can shrink soft tissue sarcomas before surgery. About 40 adults with high-risk, non-spread sarcomas will receive this combinatio…

This early-phase study tests whether combining the immunotherapy drug camrelizumab with standard radiation before surgery can help shrink tumors in people with esophageal cancer. About 25 patients will receive the combination, then undergo surgery 4-8 weeks later. Researchers wil…

This study looks at whether a three-part treatment—blocking the tumor's blood supply (TACE), precise radiation (SBRT), and drugs that boost the immune system—can help people with intermediate to advanced liver cancer that cannot be removed by surgery. The 17 participants all rece…

This early-phase study tests a new drug called NBTXR3, which is injected into tumors and activated by radiation. It is combined with an immunotherapy (anti-PD-1) to see if it can help the immune system fight advanced cancers better. The study involves about 145 people with variou…

This observational study collects extra tumor tissue from 416 people with various cancers (bladder, kidney, colorectal, head and neck, liver, lung, skin, endometrial) during routine biopsies. The goal is to develop and train a 'live tumor diagnostic platform' that can predict whe…

This study tests whether a wearable patch called TempTraq can detect fevers earlier than standard temperature checks in cancer patients receiving immunotherapy. The goal is to see if continuous monitoring reduces the risk of severe cytokine release syndrome (CRS), a serious side …

This study looks at whether bacteria in the gut and throat can predict how well stage III lung cancer patients respond to the immunotherapy drug durvalumab after chemoradiation. Researchers will collect stool, throat swabs, and breath samples from 126 participants to see if these…